Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1

Keyphrases

• Human Immunodeficiency Virus Type 1 (HIV-1) 100%
• Hydroxychloroquine 100%
• Placebo Groups 45%
• Placebo 18%
• T Cells 18%
• CD4+ 18%
• Infected Patients 18%
• Stimulation Index 18%
• Ribonucleic Acid 18%
• Virus 9%
• Randomized Placebo-controlled Trial 9%
• Inflammatory Cytokines 9%
• Cell Proliferation 9%
• Cytokine Levels 9%
• Monocytes 9%
• CD4+ T Cells 9%
• Autoimmune Disease 9%
• Polymerase Chain Reaction 9%
• Replication in Vitro 9%
• Proliferative Response 9%
• Immunological Parameters 9%
• Mitogenic Response 9%
• Mitogen 9%
• β2-microglobulin (β2-MG) 9%
• Post-transcriptional Modification 9%
• Serum Immunoglobulin G 9%
• Interleukin-6 Levels 9%
• Antimalarial Drugs 9%
• Candida 9%
• Antigen-specific Response 9%
• Viral Culture 9%
• Virologic 9%
• Type 1 Agents 9%
• Serum interleukin-6 9%

Immunology and Microbiology

• Human Immunodeficiency Virus 1 100%
• Hydroxychloroquine 100%
• T Cell 18%
• CD4 Lymphocyte Count 18%
• In Vitro 18%
• Ribonucleic Acid 18%
• Blood Plasma 9%
• Interleukin 6 9%
• Antigen Specificity 9%
• Proinflammatory Cytokine 9%
• Immunoglobulin Blood Level 9%
• T-Helper Cell 9%
• Autoimmune Disease 9%
• Mitogen 9%
• Mitogen Response 9%
• Immunoglobulin G 9%
• Beta-2 Microglobulin 9%
• Antimalarial Agent 9%
• Candida 9%
• Antigen Response 9%
• Polymerase Chain Reaction 9%
• Virus 9%
• Infection 9%
• Replication 9%